Abeona Therapeutics Inc. buy melinda
Start price
01.01.19
/
50%
€157.17
Target price
28.02.19
€214.23
Performance (%)
1.15%
End price
28.02.19
€158.98
Summary
This prediction ended on 28.02.19 with a price of €158.98. With a performance of 1.15%, the BUY prediction by melinda for Abeona Therapeutics Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Abeona Therapeutics Inc. | 39.869% | 39.869% | 52.530% | -89.803% |
iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to melinda what are the pros and cons of Abeona Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Abeona Therapeutics Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 05/03 Publication de résultats
Abeona Therapeutics Inc. est une société biopharmaceutique au stade clinique qui développe de nouvelles thérapies génétiques pour le traitement des maladies génétiques rares potentialité mortelles. Les programmes principaux de la société d'assurances ABO-102 (AAV-SGSH), générique à base de virus adéno-associés (AAV) pour le syndrome de Sanfilippo de type A (MPS IIIA) et EB-101 (greffe de peau corrigée ) pour l'épidermolysis bulleuse dystrophique récessive (RDEB). Elle développe également ABO-101 (AAV-NAGLU) pour le syndrome de Sanfilippo de type B (MPS IIIB), ABO-201 (AAV-CLN3) pour le traitement de la maladie de Batten juvénile (JNCL), ABO-202 ( AAV-CLN1) pour le traitement de la maladie infantile à Batten (INCL), EB-201 pour l'épidermolyse bulleuse, ABO-301 (AAV-FANCC) pour l ' anémie de Fanconi et ABO-302 for using the new approche, diagnostic générique CRISPR / Cas9 for the treatment of the génical maladies rares of sang. La Société dispose également d'un portefeuille de produits protéinothérapeutiques à base de plasma, comprenant un inhibiteur de protéase alpha-1 (SDF alpha) pour le MPOC héréditaire, qui utilise un procédé exclusif sans filtration à l'éthanol.
Nombre d'employés : 42 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.80
24.10.22
24.10.22
€4.50
24.10.23
24.10.23
-3.11%
25.10.23
25.10.23
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€19.80
17.10.21
17.10.21
€25.00
17.10.22
17.10.22
-15.53%
26.11.21
26.11.21
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€49.50
22.03.20
22.03.20
€75.00
04.11.21
04.11.21
-60.00%
17.10.21
17.10.21
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.50
14.03.20
14.03.20
€62.50
22.03.20
22.03.20
23.29%
22.03.20
22.03.20
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.00
15.02.20
15.02.20
€200.00
14.03.20
14.03.20
-51.97%
14.03.20
14.03.20
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€136.09
26.05.19
26.05.19
€180.40
15.02.20
15.02.20
-44.15%
15.02.20
15.02.20
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€158.98
28.02.19
28.02.19
€270.60
12.03.19
12.03.19
9.36%
12.03.19
12.03.19
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€376.59
22.05.18
22.05.18
€483.70
31.05.18
31.05.18
4.94%
31.05.18
31.05.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€273.98
14.02.18
14.02.18
€383.35
19.03.18
19.03.18
23.05%
19.03.18
19.03.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€284.13
13.02.18
13.02.18
€383.35
14.02.18
14.02.18
-9.92%
14.02.18
14.02.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€420.56
06.10.17
06.10.17
€451.00
10.10.17
10.10.17
7.28%
10.10.17
10.10.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€277.37
30.08.17
30.08.17
€563.75
18.09.17
18.09.17
34.96%
18.09.17
18.09.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€307.50
30.08.17
30.08.17
€625.00
18.09.17
18.09.17
34.96%
18.09.17
18.09.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€192.50
11.08.17
11.08.17
€250.00
24.08.17
24.08.17
23.05%
24.08.17
24.08.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€173.64
11.08.17
11.08.17
€225.50
24.08.17
24.08.17
23.05%
24.08.17
24.08.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€110.50
27.01.17
27.01.17
€225.50
07.04.17
07.04.17
3.57%
07.04.17
07.04.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€55.25
13.07.16
13.07.16
€60.89
29.07.16
29.07.16
10.61%
29.07.16
29.07.16
Could be worthwhile Investment >10% per year